Bulletin du cancer最新文献

[Proctocolectomy for familial adenomatous polyposis and other polyposis].

Bulletin du cancer Pub Date : 2025-02-20 DOI: 10.1016/j.bulcan.2024.12.014

Benjamin Fernandez, Étienne Buscail

引用次数: 0

[Prophylactic breast surgery in high-risk breast cancer patients].

Bulletin du cancer Pub Date : 2025-02-20 DOI: 10.1016/j.bulcan.2025.01.002

Lauren Darrigues, Thomas Gaillard, Jonathan Sabah, Claire Saule, Sophie Frank, Antoine de Pauw, Benoit Couturaud, Jean Philippe Binder, Jean Guillaume Feron, Enora Laas-Faron, Fabien Reyal

{"title":"[Prophylactic breast surgery in high-risk breast cancer patients].","authors":"Lauren Darrigues, Thomas Gaillard, Jonathan Sabah, Claire Saule, Sophie Frank, Antoine de Pauw, Benoit Couturaud, Jean Philippe Binder, Jean Guillaume Feron, Enora Laas-Faron, Fabien Reyal","doi":"10.1016/j.bulcan.2025.01.002","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.01.002","url":null,"abstract":"Introduction: Breast cancer associated with pathogenic variants of BRCA1 and BRCA2 genes requires specific management. This review examines the prognostic benefits, prophylactic surgical strategies, and impact on quality of life of patients at very high risk of breast cancer. Breast surgical prophylaxis concerns women at high risk of breast cancer with a risk assessment based on their personal and family history, or by diagnosis of pathogenic variants in high-risk genes. Personalized management is based on enhanced clinical and radiological monitoring, the use of predictive tools such as BOADICEA, and surgical options such as prophylactic bilateral mastectomy, which can reduce the risk of cancer by over 90 %. Although its impact on overall survival is still debated, advances in surgical techniques have significantly improved aesthetic results and patient satisfaction, thanks to modern reconstruction methods. The surgical strategy, whether primary or secondary, must be individualized, considering the patient's history, therapeutic needs, and preferences. Mastectomy with preservation of the skin envelope, often performed in one or two stages, offers significant psychosocial benefits, although radiotherapy may increase the risk of complications. Options include immediate reconstruction, by implant or autologous technique, adapted to the patient's morphology and any adjuvant treatments.Conclusion: Prophylactic bilateral mastectomy is an effective strategy for reducing the risk of breast cancer, particularly in patients with pathogenic BRCA gene variants. Personalized assessment, detailed information on risks and impacts, and the use of decision-support tools are essential to enable informed choices tailored to individual patient needs.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143473279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Impact and potential of digital technology in mind-body approaches for cancer care].

Bulletin du cancer Pub Date : 2025-02-19 DOI: 10.1016/j.bulcan.2024.12.015

Céline Ubelmann, Pierre Heudel

引用次数: 0

[French mapping of clinical pharmacy activities for older patients with cancer: A SFPO-SFPC survey].

Bulletin du cancer Pub Date : 2025-02-18 DOI: 10.1016/j.bulcan.2024.12.017

Chloé Herledan, Anne Toulemonde, Mathilde Sturmia, Anne-Laure Clairet, Aurélie Terrier-Lenglet, Maryline Legrand, Chloé Choukroun, Marine Beck, Florent Puisset, Mathieu Boulin, Christelle Mouchoux, Florian Correard

{"title":"[French mapping of clinical pharmacy activities for older patients with cancer: A SFPO-SFPC survey].","authors":"Chloé Herledan, Anne Toulemonde, Mathilde Sturmia, Anne-Laure Clairet, Aurélie Terrier-Lenglet, Maryline Legrand, Chloé Choukroun, Marine Beck, Florent Puisset, Mathieu Boulin, Christelle Mouchoux, Florian Correard","doi":"10.1016/j.bulcan.2024.12.017","DOIUrl":"https://doi.org/10.1016/j.bulcan.2024.12.017","url":null,"abstract":"Introduction: Older patients with cancer are particularly vulnerable to the risk of adverse drug events. Therefore, it is essential that pharmacists play an active role in their multidisciplinary management throughout the care pathway. The aim of this study is to provide an overview of clinical pharmacy activities integrated into multidisciplinary management in geriatric oncology in France.Method: An online survey involving pharmacists from the French societies of clinical pharmacy (SFPC) and oncology pharmacy (SFPO) was carried out between 1st May 2023 and 31 August 2023. The questionnaire focused on the description of clinical pharmacy activities associated with multidisciplinary geriatric oncology assessment developed in the institution. A single response per hospital was required.Results: Among the 70 respondents, 46 (65.7%) offer multidisciplinary geriatric oncology assessments. Clinical pharmacy activities have already been integrated to these assessments in 27 (38.6%) hospitals, and a further 10 (14.2%) are planning to implement them in the near future. These activities are carried out in parallel with medical activities, primarily after the initiation of cancer treatment and mainly on an outpatient basis. They mostly involve medication reconciliation and optimization of drug therapy. The main obstacles to their development are the lack of human resources and funding, particularly in hospitalization settings.Discussion/conclusion: Pharmacists are still insufficiently integrated into multidisciplinary geriatric oncology teams, despite their crucial role in the care pathway and the advocacy of professional societies. Changes in funding methods and the development of digital tools for city-hospital cooperation could help to promote this integration in the future.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143461023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Prejudices in the medical world regarding cancer].

Bulletin du cancer Pub Date : 2025-02-17 DOI: 10.1016/j.bulcan.2025.01.003

Jacques Robert

引用次数: 0

[Cancer and nutritional management of overweight and obesity: Practice evaluation].

Bulletin du cancer Pub Date : 2025-01-24 DOI: 10.1016/j.bulcan.2024.10.011

Léo Pernaton, Dominique Cellier, Romain Buono, Antoine Pierre, Marine Sauzet, Jean-Yves Blay, Olivia Pérol, Béatrice Fervers

{"title":"[Cancer and nutritional management of overweight and obesity: Practice evaluation].","authors":"Léo Pernaton, Dominique Cellier, Romain Buono, Antoine Pierre, Marine Sauzet, Jean-Yves Blay, Olivia Pérol, Béatrice Fervers","doi":"10.1016/j.bulcan.2024.10.011","DOIUrl":"https://doi.org/10.1016/j.bulcan.2024.10.011","url":null,"abstract":"Context: The aim of this practice evaluation was to assess weight trends during and after a nutritional intervention in cancer patients and survivors.Methods: This retrospective study was conducted between January 2014 and October 2020 in adults with different cancer types managed at the Léon-Bérard Cancer Center, undergoing treatment or during post-treatment follow-up, with a BMI≥25kg/m2 and who had at least 3 consultations with a nutrition physician. Nutritional management focused on behavioral, metabolic and nutritional aspects. Anthropometrics measurements, i.e., waist circumference, weight and BMI, were monitored prospectively during the nutritional consultation. The aim of this study was to evaluate the impact of the nutritional intervention on the anthropometrics measurements.Results: Overall, 247 patients were included in the analysis. The median duration of the nutritional intervention was 7.2months. Between the first and the last nutrition consultation, waist circumference was reduced in 97.2% of the patients, with a median loss of 10cm; weight and BMI were reduced in 85.0% and 83.8% of the patients respectively. Six months after the end of the nutritional intervention, 53.7% of patients had stable or continued reduced weight.Conclusion: This analysis of practice shows the positive impact of a nutritional intervention during cancer treatments on anthropometric parameters, and maintenance or continued weight loss at distance from the intervention in half of the patients.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143043974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bone sarcomas and cancer predisposition syndromes.

Bulletin du cancer Pub Date : 2025-01-22 DOI: 10.1016/j.bulcan.2024.10.014

Camille Tlemsani, Gaëlle Bougeard, Marion Gauthier-Villars, Philippe Denizeau, Sarah Winter, Caroline Michot, Geneviève Baujat, Brigitte Bressac, Tiphaine Adam de Beaumais, Aymeric Rouchaud, Fadila Mihoubi-Bouvier, Franck Bourdeaut, Laurence Brugières, Thierry Leblanc, Edwige Kasper, Nadège Corradini

{"title":"Bone sarcomas and cancer predisposition syndromes.","authors":"Camille Tlemsani, Gaëlle Bougeard, Marion Gauthier-Villars, Philippe Denizeau, Sarah Winter, Caroline Michot, Geneviève Baujat, Brigitte Bressac, Tiphaine Adam de Beaumais, Aymeric Rouchaud, Fadila Mihoubi-Bouvier, Franck Bourdeaut, Laurence Brugières, Thierry Leblanc, Edwige Kasper, Nadège Corradini","doi":"10.1016/j.bulcan.2024.10.014","DOIUrl":"https://doi.org/10.1016/j.bulcan.2024.10.014","url":null,"abstract":"Bone sarcomas, constituting less than 1% of malignant neoplasms across all age groups, are rare tumours possibly associated with genetic susceptibility syndromes. This review aims to provide recommendations for the detection of cancer predisposition syndromes associated with bone sarcomas and managing affected patients. Recommendations were formulated by a multidisciplinary working and reviewing group from GROUPOS and SFCE oncogenetic's group, including geneticists, oncologists, and radiologists. For various bone sarcomas including osteosarcomas, chondrosarcomas and Ewing sarcomas, we delineate tumour presentation, management strategies, and follow-up within the context of cancer predisposition syndromes. The inherited predisposition syndrome, associated with germline TP53 variants, known as the Li-Fraumeni syndrome, is the most frequent implicated in osteosarcoma cases. Other cancer predisposition syndromes, such as RB1, RECQ or CDKN2A disorders in osteosarcomas and Ollier and Maffucci diseases in chondrosarcomas, are also recognized. Additionally, we discuss rarer cancer predisposition syndromes associated with bone sarcomas and suggest tailored treatment approaches in some cancer predisposition syndromes to mitigate severe toxicities or secondary oncological events. Furthermore, we emphasize the role of identification somatic molecular variations in identifying constitutional germline variants and describe national and international screening programs, reference networks and molecular tumour boards available for collegial and collaborative management discussion. This comprehensive review provides insights into the intricate interplay between genetic predisposition, tumour biology, and therapeutic interventions in bone sarcoma patients with cancer predisposition syndrome.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patient views on continued immune checkpoint inhibition following progression in advanced melanoma: A qualitative study. 晚期黑色素瘤进展后患者对继续使用免疫检查点抑制剂的看法：一项定性研究。

Bulletin du cancer Pub Date : 2025-01-11 DOI: 10.1016/j.bulcan.2024.12.011

Chloé Prod'homme, Nicolas Sena, Emmanuelle Forestier, Rozenn Le Berre, Eve Desmedt, Laurent Mortier, Licia Touzet

{"title":"Patient views on continued immune checkpoint inhibition following progression in advanced melanoma: A qualitative study.","authors":"Chloé Prod'homme, Nicolas Sena, Emmanuelle Forestier, Rozenn Le Berre, Eve Desmedt, Laurent Mortier, Licia Touzet","doi":"10.1016/j.bulcan.2024.12.011","DOIUrl":"https://doi.org/10.1016/j.bulcan.2024.12.011","url":null,"abstract":"Introduction: Immune checkpoint inhibition has revolutionized the management of metastatic melanoma, including in the final stages of disease progression: because it is well tolerated, some teams do not discontinue it in hopes of slowing disease progression. The risks are that treatment may be continued unnecessarily, causing side effects, and reduce access to specialist palliative care, in addition to increasing the cost of treatment.Method: We explored the experiences of 10 patients in a university hospital with metastatic melanoma under continued immune checkpoint inhibitors combined with specialist palliative care. Our goal was to gain a better understanding of the advantages and disadvantages perceived by patients. The comprehensive interviews were analysed using a method inspired by grounded theory that met the COREQ international recommendation criteria.Results: Receiving the information of disease progression, continued treatment and onset of palliative care impacts patients' lives: from this point onwards, death becomes a reality and takes on the image of a sword of Damocles. The experience is anxiety-provoking because of the uncertainty of tomorrow, and painful because of the physical suffering and successive bereavements. However, far from causing depression and despair, joint oncology-palliative management is well accepted and helps to improve patients' daily lives and well-being.Conclusion: Our findings highlight patients' ambivalence. On the one hand, they recount their experiences of suffering in connection with the disease and the confrontation with death, and on the other hand, their need to continue to live and to hope. Joint care provided by oncology and palliative care teams, symbolically representing hope and death, may mirror patients' psychological mindset and provide just the support they need.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Haematopoietic stem cell donation from minor donor: Respecting laws, assessing fitness, delivering information and good care (SFGM-TC)]. [未成年人捐献造血干细胞：尊重法律、评估健康状况、提供信息和良好护理（SFGM-TC）]。

Bulletin du cancer Pub Date : 2025-01-01 Epub Date: 2024-05-16 DOI: 10.1016/j.bulcan.2024.04.002

Marie Lejeune, Bertille Menard, Sophie Servais, Christelle Andrianne, Lucie Capelle, Ségolène De Maistre, Catherine Fabaron, Marie Flata Cornier, Marie-Pierre Goutagny, Maguy Pereira, Clea Tardy, Eric Turquet, Malek Benakli, Etienne Baudoux, Solène Evard, Catherine Faucher, Gwenaelle Herrero, Léonardo Magro, Claire Geurten

{"title":"[Haematopoietic stem cell donation from minor donor: Respecting laws, assessing fitness, delivering information and good care (SFGM-TC)].","authors":"Marie Lejeune, Bertille Menard, Sophie Servais, Christelle Andrianne, Lucie Capelle, Ségolène De Maistre, Catherine Fabaron, Marie Flata Cornier, Marie-Pierre Goutagny, Maguy Pereira, Clea Tardy, Eric Turquet, Malek Benakli, Etienne Baudoux, Solène Evard, Catherine Faucher, Gwenaelle Herrero, Léonardo Magro, Claire Geurten","doi":"10.1016/j.bulcan.2024.04.002","DOIUrl":"10.1016/j.bulcan.2024.04.002","url":null,"abstract":"Haematopoietic stem cell collection from paediatric donors is a common and life-saving practice, as evidenced by the fact that there is a growing annual number of cases of transplants from minor donors among SFGM-TC centers over the last decade. Still, medical use of human tissue from a healthy and underage donor requires proper regulations and medical management. The guidelines below aim at underlining the importance of pondering the legal, medical and ethical aspects of using stem cells from healthy paediatric donors and stress out the importance of obtaining informed consent at the time of assessing HLA compatibility. Combined medical and psychological assessments are required before the donation, as well as one month later and one year later to ensure of the child's physical and mental wellbeing. Bone marrow harvest under general anaesthetics remains the preferred method of collection for children. Peripheral blood stem cell collection should only be considered for children who will not require a central venous access for collection. We aim at offering guidelines centered on the healthy child donating stem cells and his/her wellbeing, and these should be regularly reviewed as medical practices evolve.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":"S78-S86"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140961091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Updates on hairy cell leukemia (HCL) and HCL-like disorders]. [毛细胞白血病（HCL）和HCL样疾病的最新进展]。

Bulletin du cancer Pub Date : 2024-12-21 DOI: 10.1016/j.bulcan.2024.12.004

Xavier Troussard, Elsa Maitre, Urbain Tauveron-Jalenques, Jérôme Paillassa, Luca Inchiappa, Cécile Tomowiak

{"title":"[Updates on hairy cell leukemia (HCL) and HCL-like disorders].","authors":"Xavier Troussard, Elsa Maitre, Urbain Tauveron-Jalenques, Jérôme Paillassa, Luca Inchiappa, Cécile Tomowiak","doi":"10.1016/j.bulcan.2024.12.004","DOIUrl":"https://doi.org/10.1016/j.bulcan.2024.12.004","url":null,"abstract":"Hairy cell proliferations represent very different entities. They include hairy cell leukemia in its classic form (HCL), a well-defined entity, but also the variant form of HCL (LT-V ou HCL-V), whose presentation is far from HCL and whose prognosis is poorer. Other hairy cell proliferations include splenic red pulp lymphoma (SDRPL) and splenic marginal zone lymphomas (SMZL) with circulating villous cells. In this article, we emphasize the novelties concerning the different recent biological aspects of HCL, including the unusual clinical presentations but also the importance for the diagnosis of the detection of the BRAFV600E mutation, a molecular marker of the disease, and the presence of other non-canonical mutations that should be identified because of the contraindication to the use of BRAF inhibitors. Finally, the presence of a non-mutated profile of immunoglobulin heavy chains (IGHV), observed in 20% of cases, is associated with a poor prognosis. We also provide guidance in characterizing other hairy cell proliferations when examining the blood smear. The first-line treatment of HCL has recently changed and immunochemotherapy combining cladribine plus rituximab has become the gold standard. In relapsed or refractory forms, other treatments should be discussed in a multidisciplinary consultation meeting and combine BRAF inhibitors with anti-CD20 antibodies, BTK inhibitors or Bcl-2 inhibitors. The choices should be discussed according to the patient's profile but also their biological profile.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0